

**NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR
DISSEMINATION IN THE UNITED STATES**

NEWS RELEASE

For Immediate Release



**Healthcare Leaders
Income Fund**

**HEALTHCARE LEADERS INCOME FUND
ANNOUNCES COMPLETION OF OVERNIGHT OFFERING**

TORONTO, March 13, 2015 – Healthcare Leaders Income Fund (TSX: HHL.UN) (the “**Fund**”) is pleased to announce it has completed the overnight offering of 3,000,000 units of the Fund (the “**Units**”). Gross proceeds of the offering were \$30,300,000 million. In addition, the Fund has granted the underwriters an option, exercisable at the offering price for a period of 30 days from the closing of the offering, to purchase up to an additional 450,000 Units to cover over-allotments, if any.

The syndicate of underwriters for the offering was co-led by BMO Capital Markets, CIBC and Scotiabank, and included National Bank Financial Inc., Canaccord Genuity Corp., Global Securities Corporation, GMP Securities L.P., Raymond James Ltd., Desjardins Securities Inc., Dundee Securities Ltd., Industrial Alliance Securities Inc., Mackie Research Capital Corporation and Manulife Securities Incorporated (collectively, the “**Underwriters**”).

The Fund’s investment objectives are to provide Unitholders with (i) the opportunity for capital appreciation; (ii) monthly cash distributions; and (iii) lower overall volatility of Portfolio returns than would otherwise be experienced by owning Equity Securities of Healthcare Leaders directly.

The Fund invests in an equally-weighted Portfolio (at the end of each reconstitution and rebalancing) of Equity Securities of 20 Healthcare Issuers, which are issuers listed on a North American stock exchange that are included in the healthcare sector of the Global Industry Classification Standards and whose underlying business includes, but is not limited to, the provision of healthcare goods and services, including manufacturing and distributing healthcare products, equipment, supplies and technologies, producing and marketing of pharmaceuticals and biotechnology products, and/or engaging in research and development that (i) have a market capitalization of at least US\$5 billion, and (ii) have options in respect of their Equity Securities listed on a recognized options exchange.

Borden Ladner Gervais LLP acted as counsel for the Fund and the Manager and Blake, Cassels & Graydon LLP acted as counsel for the Underwriters.

Certain statements included in this news release constitute forward-looking statements, including, but not limited to, those identified by the expressions “expect”, “intend”, “will” and similar expressions to the extent they relate to the Fund, the Manager and/or the Investment Manager. The forward-looking statements are not historical facts but reflect the Fund’s, the Manager’s, and/or the Investment Manager’s current expectations regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Although the Fund, the Manager, and/or the Investment Manager believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, readers are cautioned not to place undue

reliance on such statements due to the inherent uncertainty therein. The Fund, the Manager and/or the Investment Manager undertakes no obligation to update publicly or otherwise revise any forward-looking statement or information whether as a result of new information, future events or other such factors which affect this information, except as required by law.

All capitalized terms noted herein but not defined are as defined in the final short form prospectus dated March 5, 2015 which is available on SEDAR (www.sedar.com).

For further information: please contact Paul MacDonald at Harvest Portfolios Group Inc. at pmacdonald@harvestportfolios.com or at 1-866-998-8298; or for additional information or a copy of the Prospectus, please contact your registered financial advisor.

TOR01: 5864740: v7